Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 20Carcinoma, Renal Cell 11Prostatic Neoplasms 8Uveal Melanoma 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 5Myelodysplastic Syndromes 5Clear-cell metastatic renal cell carcinoma 5Triple Negative Breast Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2

Interventions

Gemcitabine 11Cisplatin 11Nivolumab 4Doxorubicin 4pembrolizumab 3avelumab 3Radiotherapy 3Fluorouracil 3Docetaxel 3Carboplatin 3vinflunine 2pegfilgrastim 2Sunitinib 2Platinum 2Paclitaxel 2Immunoglobulin G 2Ifosfamide 2Disulfides 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1temsirolimus 1tamibarotene 1relatlimab 1merphos 1guadecitabine 1enzalutamide 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urethral Neoplasms × CTLA-4 Antigen × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡